Debt to Capital Ratio: A measurement of a company's financial leverage, calculated as the company's long-term debt divided by its total capital. Calculated as: Total Long-Term Debt / (Total Long-Term Debt + Shareholders Equity)
Inhibikase Therapeutics, Inc. (IKT) Debt to Capital Ratio data is not available.
| Income Statement Financials | |
-- |
|
$-12.73M |
|
-- |
|
-- |
|
$13.78M |
|
$-13.78M |
|
$1.04M |
|
$-12.73M |
|
$-12.73M |
|
$-12.73M |
|
$-12.73M |
|
$-12.73M |
|
$-12.73M |
|
$-13.78M |
|
$-13.78M |
|
98.31M |
|
98.31M |
|
$-0.10 |
|
$-0.10 |
|
| Balance Sheet Financials | |
$180.11M |
|
-- |
|
$1.10M |
|
$181.20M |
|
$8.30M |
|
-- |
|
-- |
|
$8.30M |
|
$172.90M |
|
$172.90M |
|
$172.90M |
|
131.69M |
|
| Cash Flow Statement Financials | |
$-27.79M |
|
$2.05M |
|
$108.46M |
|
$56.49M |
|
$139.22M |
|
$82.73M |
|
$15.31M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
21.70 |
|
-- |
|
-- |
|
|
Debt to Capital Ratio |
-- |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-27.80M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-7.37% |
|
-7.37% |
|
-7.03% |
|
-7.37% |
|
$1.31 |
|
$-0.28 |
|
$-0.28 |
|